Elevated LILRB1 in glioma was substantially correlated with the increasing WHO grade (G4 vs. G2&G3, OR = 4.172, 95%CI [2.827–6.263], P < 0.001), IDH status (WT vs. Mut, OR = 4.275, 95%CI [3.060–6.026], P < 0.001), 1p/19q codeletion (non-codel vs. codel, OR = 12.506, 95%CI [7.762–21.164], P < 0.001), Age (> 60 vs.<= 60, OR = 1.738 ,95%CI [1.198–2.539], P = 0.004) (Table 1). This evidence concerns the gene LILRB1 and central nervous system cancer.